Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1987-4-27
pubmed:abstractText
Blacks experience greater incidence, morbidity, and mortality from hypertension in comparison with whites. Blacks also respond differently to antihypertensive agents. While whites tend to respond in similar fashion to many of the different classes of antihypertensives, blacks consistently have the best response to thiazide diuretics. When a second drug is needed for blood pressure control, there are a number of choices: a beta-blocker, an alpha-beta blocker, an alphablocker, a centrally acting agent, a peripherally acting agent, an angiotensin-converting enzyme (ACE) inhibitor, or a calcium channel blocker. Choosing among these involves considerations of efficacy, likelihood of compliance, and symptomatic and metabolic side effects-all important factors. Clinical experience with the ACE inhibitors, and captopril in particular, has shown the value of adding such a drug to a diuretic regimen, both in terms of controlling blood pressure and reducing metabolic derangements, and subsequently, cardiovascular risk factors. Labetalol, the alpha-beta blocker, and prazosin, the alphablocker, have also produced good results in some studies when combined with a thiazide in black patients.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-14131417, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-319541, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-3520318, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-361368, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-383033, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-3904654, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-3915317, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-3999311, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-4217243, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-4870102, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-541040, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-6309461, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-6337951, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-6340489, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-7000296, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-7037502, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-849670, http://linkedlifedata.com/resource/pubmed/commentcorrection/3560241-920724
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0027-9684
pubmed:author
pubmed:issnType
Print
pubmed:volume
79
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
149-54
pubmed:dateRevised
2010-10-26
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Tailoring antihypertensive drug therapy for the black patient.
pubmed:publicationType
Journal Article